title: Potential role of lampalizumab for treatment of geographic atrophy.
abstract: The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.
authors.affiliation: Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: William
authors.initials: W
authors.lastname: Rhoades
authors.affiliation: Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: Drew
authors.initials: D
authors.lastname: Dickson
authors.affiliation: Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
keywords: AMD; age-related macular degeneration; complement inhibition